...
首页> 外文期刊>The Lancet >Diabetic retinopathy.
【24h】

Diabetic retinopathy.

机译:糖尿病性视网膜病变。

获取原文
获取原文并翻译 | 示例

摘要

Diabetic retinopathy is a common and specific microvascular complication of diabetes, and remains the leading cause of preventable blindness in working-aged people. It is identified in a third of people with diabetes and associated with increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure. Optimum control of blood glucose, blood pressure, and possibly blood lipids remains the foundation for reduction of risk of retinopathy development and progression. Timely laser therapy is effective for preservation of sight in proliferative retinopathy and macular oedema, but its ability to reverse visual loss is poor. Vitrectomy surgery might occasionally be needed for advanced retinopathy. New therapies, such as intraocular injection of steroids and antivascular endothelial growth-factor agents, are less destructive to the retina than are older therapies, and could be useful in patients who respond poorly to conventional therapy. The outlook for future treatment modalities, such as inhibition of other angiogenic factors, regenerative therapy, and topical therapy, is promising.
机译:糖尿病性视网膜病是糖尿病的常见且特定的微血管并发症,并且仍然是劳动年龄人群可预防的失明的主要原因。在三分之一的糖尿病患者中发现了这种疾病,并且这种疾病与威胁生命的系统性血管并发症(包括中风,冠心病和心力衰竭)的风险增加有关。最佳控制血糖,血压和可能的血脂仍然是降低视网膜病变发展和进展风险的基础。及时的激光治疗对于增生性视网膜病变和黄斑水肿的视力保持有效,但其逆转视力丧失的能力很差。晚期视网膜病变有时可能需要进行玻璃体切割手术。眼内注射类固醇和抗血管内皮生长因子药物等新疗法对视网膜的破坏性不如旧疗法,并且可能对常规疗法反应差的患者有用。诸如抑制其他血管生成因子,再生疗法和局部疗法等未来治疗方式的前景是有希望的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号